Bernstein cuts Jazz Pharmaceuticals stock price target on Zepzelca outlook
Bernstein lowered its price target for Jazz Pharmaceuticals (JAZZ) to $220 from $229, citing competition from Amgen's Imdelltra for Zepzelca in small cell lung cancer. Jazz's stock is up 79% in the past year. Jazz reported Q3 revenue of $1.24B, up 10% YoY, but a loss per share of $3.88 due to an IPR&D charge. Baird reiterated an Outperform rating with a $280 target.
How this was made
The 30-second read
Why it matters
The price‑target cut may trigger short‑term sell pressure, but Jazz's broader portfolio could provide resilience.
Market read
Analyst downgrade based on competitive threat to a key oncology drug, with potential near‑term stock impact.
What to watch
Jazz's sleep franchise and other product lines may offset oncology weakness.
Background
Bernstein SocGen Group adjusted its valuation model for Jazz after reviewing Amgen's trial data.
Ticker impact
Bernstein lowered Jazz Pharmaceuticals' price target to $220, citing expected Zepzelca sales decline from Amgen's Imdelltra competition.
likely downward pressure as the market prices in weaker Zepzelca outlook.
Target cut reflects anticipated loss of market share, which typically triggers sell‑offs.
Market effects
Small‑cell lung‑cancer therapeutics may see competitive pressure, affecting peers in oncology.
US biotech sector could see modest pullback as analysts reassess similar pipelines.
Limited to investors tracking oncology drug pipelines and related biotech stocks.
Counterpoint
If Amgen's Imdelltra faces regulatory or efficacy setbacks, Jazz could retain Zepzelca market share.
Key entities
- companyJazz Pharmaceuticals
US‑listed biopharma with oncology, sleep, and epilepsy products.
- companyAmgen
Competitor launching Imdelltra in small‑cell lung cancer.
